header  midspacer  ad 
February 20th, 2012   ECLINIQUA .COM    ARCHIVES    CHI CONFERENCES    ADVERTISING       rss RSS       LOGIN     REGISTER                                
 
 
 
 
 
 
Bio-IT World Clinical Trials Survey Results 
 
This brief survey is intend to provide insight into three areas: 
• Key clinical process challenges facing the industry 
• Trends in cloud computing usage and projects growth within the clinical sector 
• Usage of outsources services and projected growth 

Access Survey 

 
 
LATEST eNEWSLETTERS 
eCliniqua 
January 23, 2012 
 
 
 
 
Contact the Editor 
We invite your comments and feedback for this edition of Weekly Update. 

Allison Proffitt 
Managing Editor 
 
 

CLINICAL NEWS & ANALYSIS

 
Budget Woes Stall Clinical Trials and Stymie Sites 
Bio-IT World (Feb 20 2012) Trial Design and Logistics 

Imagine buying a new car or a new house but not knowing the price until the papers have already been drawn up and it’s time to sign on the dotted line. According to Christine Pierre, President of RxTrials, that’s exactly the situation investigative sites face as they attempt to negotiate budgets and contracts for clinical trials.

How Does Big Pharma Boost Its Returns? 
Fool.com (Feb 19 2012) Electronic Data Capture (EDC) 
Break it down with the DuPont Formula.
Deadly bird flu studies to stay secret for now: WHO 
reuters.com (Feb 17 2012) Electronic Data Capture (EDC) 
GENEVA/LONDON (Reuters) - Two studies showing how scientists mutated the H5N1 bird flu virus into a form that could cause a deadly human pandemic will be published only after experts fully assess the risks, the World Health Organization (WHO) said on Friday.
 
 
 

ELSEWHERE IN THE PRESS

 
Why Bristol-Myers Squibb Could Break Out This Year 
The Motley Fool (Feb 15 2012) Electronic Data Capture (EDC) , Trial Design and Logistics 
Why Bristol-Myers Squibb Could Break Out This Year
How to Successfully Repurpose a Drug 
WSJ Blogs (Feb 14 2012) Regulatory Issues & Drug Safety , Trial Design and Logistics 
As today’s WSJ reports, there is growing interest in running clinical trials that repurpose drugs that have already won FDA approval for another disease.
FDA unveils biosimilars guidance 
Nature Publishing Group (Feb 9 2012) Regulatory Issues & Drug Safety , Trial Design and Logistics 
Move could open the door to cheaper generic versions of biological drugs.
Craig Lipset on the Recruitment Mind Shift 
Applied Clinical Trials (Feb 9 2012) Trial Design and Logistics 
REMOTE is the first-ever ran­domized clinical trial under an in­vestigational new drug (IND) application in which the study is managed entirely us­ing electronic tools and allows subjects to participate in the clinical trial regardless of their proximity to clinical sites. Pfizer’s pi­lot project uses mobile phone and Web-based technology to collect necessary data for the trial, without clinic visits. The trial was announced last June. And this month  ACT, Editor-in-Chief Lisa Henderson talked t
Researchers defend benefits of mutant flu research 
Nature Publishing Group (Jan 25 2012) Regulatory Issues & Drug Safety , Trial Design and Logistics 
A dire lack of global virus surveillance doesn't negate the potential of mutation monitoring, argue two researchers behind the mutant flu research.
 
 
 

ELSEWHERE IN THE PRESS

 
Picture Perfect: Imaging in Drug Discovery and Translational Medicine 
Bio-IT World (Feb 7 2012) Market Insights , Trial Design and Logistics 
Bio-IT World | Imaging in drug discovery has been rising to the forefront of conversations more and more recently. Managing editor Allison Proffitt spoke with Ken Kilgore, Director of Immunology Pharmacology at Janssen Research & Development (formerly Centocor Research & Development), a Johnson & Johnson company, about how—and why—imaging’s role is changing in drug discovery.
Dana-Farber lands $10M for cancer research 
Business News (Feb 1 2012) Trial Design and Logistics 
Dana-Farber Cancer Institute has been awarded a $10 million grant rom the Massachusetts Life Sciences Center to support the expansion of its cancer imaging research program, Mass High Tech reports. Funding for the grant comes from the state’s 10-year, $1 billion Life Sciences Initiative. The money will support the establishment of Dana-Farber's Molecular Cancer Imaging Facility, a $20 million research initiative in South Boston to develop new molecular imaging probes. As MHT reports, the imaging facility will expand several of Dana-Farber’s basic and clinical research enterprisesfocused on developing targeted cancer therapies.
Bush Doctrine: The Pharmaceutical Safety Data Problem 
Bio-IT World (Jan 27 2012) Regulatory Issues & Drug Safety , Trial Design and Logistics 
Bio-IT World | The Bush Doctrine: What the industry calls “safety data” covers everything from discovery-oriented in vitro or cell based studies to extensive GLP toxicology study data, voluminous clinical study records, and post-marketing/pharmacovigilance systems. It leads one to wonder: does anyone have informatics systems that allow safety investigators across the pharma enterprise to effectively mine this ocean of information?
 
 
 
 
 
 
follow join 
 
COMPLIMENTARY WHITEPAPER 
Turning Genomics Data into Practical Insight 
 
Sponsored by: SGI 
With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: 

•Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 

•Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 

Download Now 
 
 
 

 
 

 

 

 

 

 

 
 

 

 









See all links >>
 
 

 

Cambridge Healthtech Institute | 250 First Ave Suite 300 | Needham MA 02494 | USA